Badine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Badine

Quick Facts

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical (Cream, Ointment, Lotion)
Pharmacological class Synthetic Adrenocorticosteroid
Common use Reducing skin inflammation and itching
Origin Synthetic

The Core Identity: What Type of Medicine is Badine?

Badine is a medicinal preparation whose active component, Betamethasone Dipropionate, classifies it as a synthetic adrenocorticosteroid. This compound belongs to the powerful topical steroid pharmacological class, used exclusively for application directly on the skin. It is derived from the parent steroid betamethasone, a synthetic analog of prednisolone, and its primary action involves acting as an anti-inflammatory and immunosuppressive agent.

The active ingredient's complex chemical definition confirms its synthetic origin. This classification establishes that the preparation acts directly on cellular pathways to mitigate inflammation, a property recognized across the entire class of glucocorticoids.

Composition and Form: What is Betamethasone Dipropionate Made Of?

The core substance is Betamethasone Dipropionate, which is the 17,21-dipropionate ester of betamethasone. This esterification is a modification designed to enhance the molecule's ability to penetrate the protective barrier of the skin, a feature critical for high-potency formulations. This single-ingredient product is typically a prescription-only (Rx) medication and is available in various topical preparations, most commonly as a cream, ointment, or lotion.

For instance, the ointment form is a differentiating factor often favored for its highly occlusive nature, making it suitable for treating thick, chronic skin lesions via the topical route of administration. The final formulation combines the active ingredient with a basic pharmaceutical vehicle, which dictates the physical properties of the medicine.

General Purpose: Why is This Type of Corticosteroid Used?

The general purpose of this potent medicine is to provide relief from intense inflammatory and pruritic (itching) manifestations on the skin. Betamethasone Dipropionate acts primarily through its established anti-inflammatory and immunosuppressive actions. Products containing this corticosteroid are used to alleviate inflammation and suppress the localized immune response in the skin. This function directly addresses the symptoms of skin conditions responsive to this class of drug, providing an example of its typical use in reducing the discomfort and appearance of a severe flare-up.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Badine?

Possible Side Effects and Safety Information

Regulatory documentation for Betamethasone Dipropionate (Badine) classifies possible adverse reactions primarily based on the system or organ affected and the reported frequency.

Documented Adverse Reactions and Frequency

Adverse reactions are mainly associated with Skin and Subcutaneous Tissue Disorders (dermatologic effects). Local reactions, such as burning, itching (pruritus), irritation, and dryness, are documented, often reported infrequently or through postmarketing surveillance. In controlled adult trials, stinging was reported at an incidence of 0.4%. Other local effects listed include folliculitis, hypertrichosis, acneiform eruptions, and signs of skin atrophy.

Systemic Risk and Serious Adverse Reactions

As a high-potency topical steroid, systemic absorption may occur, leading to potential effects on the Endocrine System. Serious adverse reactions documented in official labeling include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the manifestations of Cushing's syndrome, which are generally rare and more likely with prolonged or excessive use. Systemic absorption may also affect the Ophthalmic System, with potential for the development of Cataracts or Glaucoma. Intracranial hypertension has been specifically reported in pediatric patients.

Safety Considerations and Restrictions

The safety profile includes specific considerations for duration of exposure, as the risk of systemic effects and local reactions like striae increases with prolonged use and the application of occlusive dressings. Pediatric patients are noted to have greater susceptibility to systemic toxicity, including specific signs of adrenal suppression such as linear growth retardation. Safety restrictions state that the medicine should not be used in cases of hypersensitivity to any component and should not be applied to areas such as the face, groin, or axillae.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Badine indicates that the most common presentation is profound hypersedation or drowsiness, which can progress to serious Central Nervous System (CNS) depression, including stupor and deep coma. However, paradoxical CNS effects like excitement, seizures, tremor, and hallucinations have also been documented.

Serious risks primarily involve the Cardiovascular System, including low blood pressure (hypotension), a rapid or pounding heartbeat, and the potential for a dangerous heart rhythm abnormality known as QT interval prolongation. Other symptoms may include pronounced anticholinergic effects such as dry mouth, difficulty urinating, and blurred vision.

When to Seek Emergency Medical Attention

Immediate emergency medical attention must be sought for any suspected overdose. Call an emergency number right away if the person experiences any of the following severe symptoms:

  • Seizures or convulsions
  • Coma or unresponsiveness
  • Severe drowsiness or stupor from which they cannot be roused
  • Difficulty breathing
  • An unsafe or irregular heart rhythm

Overdose management is symptomatic and supportive, as there is no specific antidote. The risk of severe, life-threatening events, such as respiratory depression and prolonged coma, is significantly increased when Badine is taken in combination with alcohol or other CNS depressants.

Therapeutic Uses of Badine

What Badine Treats: Main Uses and Benefits

Badine provides supportive benefit and may be part of symptomatic management, generally applied in contexts involving noticeable discomfort. The medication is relevant in contexts marked by increased discomfort or tension, applied in situations involving episodic or fluctuating manifestations. The medication is used in the management of symptoms of Menière’s syndrome, which often include vertigo, tinnitus, and hearing loss.

The medication is relevant for easing symptoms that interfere with daily comfort. Badine is applied in addressing symptoms related to systemic imbalance, and is commonly used when short-term symptomatic assistance is needed. It contributes to general well-being during symptomatic phases, assists with maintaining functional stability, and provides supportive relief when symptoms interfere with routine activities.

“This support offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Pronounced Symptom Intensity

Regulatory References

  1. European Commission official record for Betahistine

Eligibility and Restrictions for Use

Official Eligibility Profile for Badine

Regulatory documentation defines who can and cannot use Badine based on a patient's medical history, age, and organ function. This profile is structured by classifications like Contraindications and Restrictions.

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to Badine or its components.
Absolute Contraindication Patients with Severe Hepatic Impairment (Child-Pugh Class C) or Severe Renal Impairment.
Absolute Contraindication Individuals with a history of drug-related angioedema following previous Badine use.
Use Restricted Patients with Moderate Renal or Hepatic Impairment (requiring dose adjustment and monitoring).
Use Not Recommended Children and Adolescents (under 18 years), as safety and efficacy are not established in this age group.
Use Requires Caution Older Adults (over 65 years), often necessitating a low starting dosage.
Conditional Use Pregnancy and Lactation: Use is generally not recommended unless explicitly justified by the prescriber after assessing the individual risk versus benefit.

These official statements delineate the boundaries of safe use by excluding populations with high, unacceptable risks and imposing strict conditional requirements on groups with moderate risk or insufficient data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Badine (Betamethasone Dipropionate topical) is primarily structured around the potential for systemic glucocorticoid exposure due to its class and administration route. Regulatory documentation emphasizes two main interaction domains rather than metabolic or transporter-based drug-drug interactions.


Pharmacodynamic and Exposure-Related Interactions

Interaction Type Official Regulatory Statement
Pharmacodynamic Interaction Co-administration with other corticosteroid-containing products (topical or systemic) results in an increased total systemic glucocorticoid exposure.
Exposure Constraint Application methods that increase absorption, such as using occlusive dressings or applying to large surface areas, are officially noted as factors that modify drug exposure.
Timing Rules No mandatory timing or dose separation rules are documented in the labeling for co-administration with other medicinal products.
Food/Herbal Products No formal interactions with food, alcohol, or specific herbal products are explicitly documented in the regulatory labeling.

Population-Specific Considerations

Official labeling notes that the risk of interaction-related systemic effects is increased in certain populations. Pediatric patients are more susceptible to systemic toxicity and Hypothalamic-Pituitary-Adrenal (HPA) axis suppression due to a higher skin surface area to body mass ratio. Similarly, patients with liver impairment have an increased risk for systemic adverse reactions resulting from exposure.

Mechanism of Action

Badine is a bisphosphonate derivative that selectively targets and binds to the hydroxyapatite crystal surface of the bone matrix. This molecular interaction physically localizes the compound to areas undergoing active resorption, specifically at the site of osteoclast activity. Upon internalization by active osteoclasts, Badine enters the mevalonate pathway. It non-hydrolytically inhibits the enzyme farnesyl pyrophosphate synthase (FPPS). The inhibition of FPPS prevents the essential prenylation of signaling proteins, including small GTPases. The lack of these modified proteins disrupts the osteoclast cytoskeleton and trafficking machinery, leading to programmed cell death, or apoptosis. By reducing the activity and lifespan of the osteoclast population, Badine mechanistically decreases the rate of bone mineral removal, resulting in a net decrease in the overall bone turnover rate.

Dosage and Administration Information

Badine, which contains the active ingredient Betamethasone Dipropionate, is strictly an external topical medicine and is not intended for oral, ophthalmic, or intravaginal use. The available 0.05% formulations, such as cream, ointment, and lotion, must be applied as a thin film to the affected skin area.

The established dosing schedule requires application once or twice daily, depending on the specific product and clinical context. Specifications for use include a strict quantitative limit on the amount of high-potency product used: the application must not exceed 50 grams or 50 mL per week.

The overall duration of continuous treatment is intended to be short. Use is generally restricted to no more than two consecutive weeks, and the application should be discontinued immediately upon achieving control of the condition. For certain specific forms, such as the spray for plaque psoriasis, the maximum duration may extend to four weeks.

Procedural constraints dictate that the treated area must not be covered or wrapped with occlusive dressings unless specifically instructed by a prescribing practitioner. Furthermore, application should be avoided on highly sensitive areas, including the face, groin, and axillae (underarms). Use of this potent medicine is generally not recommended for pediatric patients under the age of 12 or 13.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Badine

Evidence for Use in Plaque Psoriasis

Research for plaque psoriasis includes short-term clinical trials. These studies were conducted during periods of increased symptom activity and often involved comparing the active medicine against a vehicle (a cream or ointment that contains no active drug) or other similar treatments. The primary populations studied were adults and adolescents who had mild to moderate psoriasis. Researchers primarily focused on objective, investigator-assessed outcomes related to skin clearance, using specific tools like the Psoriasis Area and Severity Index (PASI) to measure changes in redness, scaling, and thickness.

Studies reported how symptoms evolved in the observed populations over defined time intervals, usually 2 to 4 weeks. Findings describe patterns observed in the studies, which involved measuring the degree of change in the skin condition according to the assessments used in the trial. Research provides insight into short-term changes by monitoring these outcomes.


Evidence for Use in Corticosteroid-Responsive Dermatoses

This block of evidence describes the research for a broader category of conditions characterized by inflammatory or irritative states. Studies have included standard controlled trials that monitored outcomes related to physical discomfort and inflammatory states, including changes observed in swelling and redness. Furthermore, research examined the activity of the medicine using a regulatory method called the vasoconstrictor assay, a measure used in studies to evaluate activity when applied to the skin. Research also describes patterns in patient-reported outcomes, such as the patient-reported intensity of itching (pruritus) during the study period.


What Remains Uncertain in the Research Landscape

Clinical trials used in research exploring short-term symptom changes typically had limited follow-up durations, with primary efficacy data often available for only 2 to 4 weeks. Because of this structure, information for long-term outcomes remains limited regarding the use of Betamethasone Dipropionate. The durability of symptom changes after treatment is stopped is not characterized by the core short-term efficacy research. The evidence primarily contributes to understanding symptom patterns during acute or episodic changes.

Limited information is also available for certain groups, such as younger pediatric populations (below 12 years), where data for certain outcomes remain insufficient. Furthermore, some evidence relied upon in the broader evidence landscape is derived from trials involving the medicine in fixed-dose combination products, which complicates the interpretation of the isolated effect.

Key Studies & References

  1. Label: BETAMETHASONE DIPROPIONATE cream - DailyMed (Regulatory document for indications, dosage, and age-related eligibility)
  2. Public Assessment Report Scientific discussion Daivobet gel (Calcipotriol and betamethasone) DK/H/0279/002/DC - CBG-Meb (EMA-related document on fixed-dose combination, HPA axis, and vasoconstrictor study)

Frequently Asked Questions (FAQ)

Common questions about Badine (FAQ)


Q: How quickly should I expect to feel the effects of Badine?

A: Clinical trials and official information have noted that improvement in skin condition is commonly observed within three to four days after starting topical treatment. This observation is based on studies assessing the medicine's activity and short-term effectiveness for its main indications.

Q: Does Badine need to be taken at a specific time of day?

A: According to the official product information, Badine is typically applied once or twice daily. However, regulatory documents do not specify a mandatory time for application relative to the clock, mealtimes, or sleep.

Q: What should I do if I forget to take a dose of Badine?

A: Regulatory-derived patient information suggests that, if a dose is missed, it is generally recommended to skip the missed dose if the time for the next scheduled application is near. You would then resume the regular application schedule.

Q: What happens if I stop taking Badine suddenly?

A: Official warnings and precautions state that sudden discontinuation after prolonged or excessive use may lead to signs and symptoms associated with steroid withdrawal. In these cases, temporary supplemental systemic corticosteroids may be required under medical supervision.

Q: Will Badine affect the results of any routine blood tests?

A: Systemic absorption of the corticosteroid can potentially cause Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This means it may affect the body’s natural production of cortisol, and these changes can be detected by specific endocrine blood tests.

Q: How long does Badine stay in your system after the last dose?

A: Official regulatory documents indicate that, once absorbed, topical corticosteroids are handled by the body like other steroids: they are primarily metabolized in the liver and excreted by the kidneys and bile. The precise duration the medicine remains in the system is not specifically provided in the product labeling.

Q: Does Badine interact with common supplements like vitamins or herbal remedies?

A: According to the official regulatory labeling for this topical medicine, formal interactions with food, alcohol, or specific herbal products have not been explicitly documented in studies.

Q: Can Badine affect blood pressure?

A: Official warnings note that excessive systemic absorption of Badine can lead to side effects associated with Cushing's syndrome. This condition is known to be associated with high blood pressure (hypertension).

Q: What is the maximum duration a person can usually be on Badine?

A: Official regulatory documents state that the continuous duration of treatment should generally not exceed two consecutive weeks for most uses. However, the maximum duration for specific augmented forms used to treat certain conditions may be up to four weeks.

Q: Can Badine be taken on an empty stomach?

A: Badine is strictly a topical preparation, available as a cream, ointment, or lotion, and is not for oral use. Therefore, the concept of taking it on an empty stomach does not apply to this external medicine.

Q: Is it better to take Badine with food or without?

A: Since Badine is strictly a topical preparation for external use only and is not meant to be swallowed, the concept of taking it with or without food does not apply.

Q: Is there any research on Badine use during pregnancy?

A: Official information states that data are not available to definitively establish drug-associated risk in pregnant individuals. However, official labeling mentions that observational studies suggest a potential increased risk of low birthweight in infants associated with the use of potent topical corticosteroids in large quantities.

Q: Is it safe to breastfeed while taking Badine?

A: There are currently no data on whether this medicine is excreted in breast milk or its effects on a nursing infant. Safety considerations in the labeling suggest that topical application should be limited to the smallest skin area and the shortest duration possible while breastfeeding.

Q: Can Badine be crushed or split if a person has trouble swallowing pills?

A: Badine is a topical product available in forms like cream, ointment, or lotion, and it is not intended for oral use. As such, swallowing or crushing pills is not required for administration.

Q: Is Badine an antibiotic, an antiviral, or something else?

A: Badine is classified as a synthetic adrenocorticosteroid, which belongs to the potent topical corticosteroid class of medicines. Its primary action is as an anti-inflammatory and anti-itch (anti-pruritic) agent, not as an antibiotic or antiviral.

Q: Can Badine interact with alcohol?

A: Formal interactions between Badine and alcohol are not explicitly documented in the official regulatory labeling for this topical medicine.

Q: Does Badine cause weight gain or weight loss?

A: While weight change is not listed as a common side effect, systemic side effects like Cushing's syndrome may involve a change in weight. This change can be a manifestation of adrenal gland problems associated with increased absorption.

Q: Can Badine cause mood changes or anxiety?

A: Changes in mood, including feeling confused or drowsy, have been associated with systemic absorption, particularly when the medicine is used for a prolonged period. These effects may be signs of adrenal gland problems.

Q: Is Badine a controlled substance?

A: Regulatory information confirms that this medicine is not scheduled under the Controlled Substances Act (CSA) and is not considered a controlled drug.

Q: What are the signs of an allergic reaction to Badine?

A: Regulatory-derived patient information states that signs of a serious allergic reaction may include sudden swelling of the lips, mouth, throat, or tongue, and difficulty breathing. Hypersensitivity to any component is listed as a contraindication.

Q: Does taking Badine affect fertility?

A: Regulatory documents state that long-term animal studies to evaluate the specific effect of topical corticosteroids on fertility have not been performed.

Q: What should be avoided when combining Badine with cold or flu medicine?

A: Official drug interaction information includes a cautionary note about co-administration with other corticosteroid-containing products, as this is explicitly noted to increase the total systemic exposure to glucocorticoids.

Q: How is the effectiveness of Badine usually monitored?

A: Effectiveness is typically assessed by objective measures of skin clearance, such as a reduction in redness, scaling, and skin thickness. It is also monitored by tracking patient-reported symptoms, particularly the intensity of itching.

How should Badine be stored and disposed of?

The storage and disposal requirements for Badine (Betamethasone Dipropionate) are officially defined to maintain drug stability and ensure safety.

Required Storage Conditions

Labeled Storage Temperature Store at controlled room temperature between mathbf20 C and mathbf25 C (68 F to 77 F).
Handling Requirements Keep from freezing and do not expose the product to temperatures above 25 C.
Container and Protection Store the product in a well-closed container and protect it from light.
Stability After Opening Specific formulations, such as the topical spray, must be discarded 4 weeks after the container is first opened.

Disposal and Safety

Child-Protection Storage Must be stored out of the sight and reach of children.
Official Disposal Rules Disposal of any unused or expired product must be carried out in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Badine found in:

A-Z Index: